Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as an Adjuvant Treatment in Endometrial Carcinoma

• Status: Not yet recruiting
• Trial end date: 2025-11-01
• Target enrollment: 0
• Participant gender: Female

Summary

Endometrial cancer, the most common gynecologic cancer worldwide, is steadily increasing in developed countries.The early-stage forms of endometrial cancer are usually highly curable by surgical treatment alone, whereas advanced stages require adjuvant interdictions such as radiotherapy and chemotherapy. Platinum and anthracycline drugs have long been used as standard adjuvant chemotherapy drugs for advanced and recurrent endometrial carcinomas. In one study, the standard combination adjuvant treatment with AP was found to be more effective as an adjuvant therapy than whole abdominal irradiation

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Sohag University
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Paclitaxel

Criteria

Inclusion Criteria:• Age group: Histologically diagnosed with primary endometrial carcinoma

• more than 20 years old.

• Any histological type of endometrial carcinoma

• Stage III, IV

• Stage one I or II with one or more of the following factors:

1. Histologic grade 3 endometroid carcinoma with myometrial invasion still within half of the myometrium

2. histological grade 1,2 endometroid carcinomas with invasion of over half of myometrium

3. cervical stromal invasion

4. vascular invasion; or

5. serous carcinoma, clear cell carcinoma, or undifferentiated carcinoma

• performance status 0-2

• adequate function of all major organs

Exclusion Criteria:

• • Pt has received prior radiation or chemotherapy.

• Pt with sarcomatous component

• Metastatic endometrial carcinoma

• Other malignancy

• Unfit patient for chemotherapy